Log in with your email address username.


[Comment] Dupilumab for atopic dermatitis

In The Lancet, the LIBERTY AD CHRONOS study by Andrew Blauvelt and colleagues1 of long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids portends a coming revolution in the treatment of atopic dermatitis. Dupilumab seems to be for atopic dermatitis what etanercept was to psoriasis, an effective, safe treatment that might represent a quantum leap forward in our ability to help to improve the lives of patients.1 For individuals with moderate-to-severe atopic dermatitis, quality of life is greatly affected and can be worse than in patients with psoriasis.